Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 17/20 | 0.69 |
| ▸ | CTSB | P07858 | 7/20 | 0.69 |
| ▸ | CTSS | P25774 | 2/20 | 0.64 |
| ▸ | CTSK | P43235 | 2/20 | 0.64 |
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1930834 | 1.00 | CAPN1 (0.69) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL1335435 | 0.94 | CAPN1 (0.68) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL1335434 | 0.94 | CAPN1 (0.68) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL1930492 | 0.89 | CAPN1 (0.86) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL1930489 | 0.89 | CAPN1 (0.86) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL1333082 | 0.89 | CAPN1 (0.82) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL1333084 | 0.89 | CAPN1 (0.82) | CAPN1CTSBCTSSCTSKCTSL | |
| Hydrochloric Acid SCHEMBL29483189 | 0.88 | CAPN1 (0.84) | CAPN1CTSBCTSSCTSKCTSL | |
| Hydrochloric Acid SCHEMBL1333121 | 0.88 | CAPN1 (0.84) | CAPN1CTSBCTSSCTSKCTSL | |
| Hydrochloric Acid SCHEMBL1333122 | 0.88 | CAPN1 (0.84) | CAPN1CTSBCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956093-B2 | Substituted amides, their preparation and use | ABBOTT GMBH & CO. KG (DE) | 2011-06-07 | — | — | US | disclosed |
| US-20080113989-A1 | For example, N-(1-Carbamoyl-1-oxo-3-phenylpropan-2-yl)-2-(E-2-(4-(1-pyrrolidinylmethyl)phenyl)ethen-1-yl)benzamide; calcium channel blockers; cardiovascular disorders; antiarthritic agents; inhibitors of enzymes, especially cysteine proteases such as calpain and cathepsins | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7276500-B2 | Calcium channel blockers; cardiovascular disorders; antiarthritic agents | ABBOTT GMBH & CO. KG (DE) | 2007-10-02 | — | — | US | disclosed |
| US-6753327-B1 | NEURODEGENERATIVE DISORDER OR NEURONAL DAMAGE TREATMENT; INHIBITORS OF CALPAIN OR CATHEPSIN CYSTEINE PROTEASES; ANTIISCHEMIC AGENTS; REPERFUSION INJURIES | ABBOTT GMBH & CO. KG (DE) | 2004-06-22 | — | — | US | disclosed |
| US-20040082569-A1 | Calcium channel blockers; cardiovascular disorders; antiarthritic agents | ABBOTT GMBH & CO., KG | 2004-04-29 | — | — | US | disclosed |
| EP-1073641-B1 | NEW SUBSTITUTED AMIDES, THEIR PRODUCTION AND THEIR USE | ABBOTT GMBH & CO KG (DE) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082569-A1 | Calcium channel blockers; cardiovascular disorders; antiarthritic agents | CACNA1C, CACNA1E, RYR1 | CAPN1 862/4885CTSB 2425/4885CTSS 2541/4885 |
| US-20080113989-A1 | For example, N-(1-Carbamoyl-1-oxo-3-phenylpropan-2-yl)-2-(E-2-(4-(1-pyrrolidinylmethyl)phenyl)ethen-1-yl)benzamide; calcium channel blockers; cardiovascular disorders; antiarthritic agents; inhibitors of enzymes, especially cysteine proteases such as calpain and cathepsins | CAPN1, CAPNS1, CAPN2 | CAPN1 1/4885CTSB 10/4885CTSS 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.